Comparative Pharmacology
Head-to-head clinical analysis: MIVACRON versus ROCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACRON versus ROCURONIUM BROMIDE.
MIVACRON vs ROCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting muscle contraction.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
0.6 mg/kg IV bolus for intubation; maintenance: 0.1-0.2 mg/kg IV bolus as needed or continuous infusion 5-10 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Terminal elimination half-life: 1.4-2.4 minutes (distribution half-life: 3-5 minutes); recovery index (25-75%): 12-16 minutes; clinical duration (dose-dependent): 30-45 minutes (0.6 mg/kg) to 70-90 minutes (1.2 mg/kg)
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Renal: 33% unchanged; Biliary/fecal: 33% (as parent and metabolite); Hepatic metabolism: ~10-20%; remainder: unknown
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker